Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity.

https://escholarship.org/uc/item/5x17v25m

Cell, 165(4)

0092-8674

Jais, Alexander
Solas, Maite
Backes, Heiko
et al.

2016-05-01

10.1016/j.cell.2016.03.033

Peer reviewed
Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity

Graphical Abstract

Highlights

- Acute high-fat feeding suppresses GLUT1 expression at the blood-brain barrier (BBB)
- Macrophages at the BBB increase VEGF expression upon prolonged HFD feeding
- Inducible GLUT1 deletion in brain endothelial cells leads to increased VEGF secretion
- Myeloid-cell-specific disruption of VEGF impairs cognitive function in obesity

Authors

Alexander Jais, Maite Solas, Heiko Backes, ..., Napoleone Ferrara, Gerard Karsenty, Jens C. Brüning

Correspondence

bruening@sf.mpg.de

In Brief

Acute high-fat feeding suppresses brain glucose uptake. To preserve cognitive function after prolonged feeding on a high-fat diet and to forestall neurodegeneration in obesity, there is a compensatory upregulation of glucose transporters at the blood-brain barrier as a result of inflammatory signals from perivascular macrophages.
Myeloid-Cell-Derived VEGF Maintains Brain Glucose Uptake and Limits Cognitive Impairment in Obesity

Alexander Jais,1,2,11 Maite Solas,1,2,11 Heiko Backes,1 Bhagirath Chaurasia,1 André Kleinridders,1,4,5 Sebastian Theurich,1,2 Jan Mauer,1,2 Sophie M. Steculorum,1,2,3 Brigitte Hampel,1,2,3 Julia Goldau,1,2,3 Jens Alber,1,2,3 Carola Y. Förster,6 Sabine A. Eming,3,7 Markus Schwaninger,8 Napoleone Ferrara,9 Gerard Karsenty,10 and Jens C. Brüning1,2,3,5,*

1Department of Neuronal Control of Metabolism, Max Planck Institute for Metabolism Research, Glueuler Strasse 50, 50931 Cologne, Germany
2Center for Endocrinology, Diabetes and Preventive Medicine (CEDP), University Hospital Cologne, 50924 Cologne, Germany
3Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD) and Center of Molecular Medicine Cologne (CMMC), University of Cologne, Joseph Stelzmann Strasse 26, 50931 Cologne, Germany
4German Institute of Human Nutrition Potsdam-Rehbruecke, Central Regulation of Metabolism, Arthur-Scheunert-Allee 114-116, 14558 Nuthetal, Germany
6Department of Anaesthesia and Critical Care, University of Würzburg, Oberdörrbacher Strasse 6, 97080 Würzburg, Germany
7Department of Dermatology, University of Cologne, 50937 Cologne, Germany
8Institute of Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Ratzeburger Allee 160, 23562 Lübeck, Germany
9Moores Cancer Center, University of California, 3855 Health Sciences Drive, La Jolla, CA 92093, USA
10Department of Genetics and Development, Columbia University, 701 West 168th Street, New York, NY 10032, USA
11Co-first author
*Correspondence: bruening@sf.mpg.de
http://dx.doi.org/10.1016/j.cell.2016.03.033

SUMMARY

High-fat diet (HFD) feeding induces rapid reprogramming of systemic metabolism. Here, we demonstrate that HFD feeding of mice downregulates glucose transporter (GLUT)-1 expression in blood-brain barrier (BBB) vascular endothelial cells (BECs) and reduces brain glucose uptake. Upon prolonged HFD feeding, GLUT1 expression is restored, which is paralleled by increased expression of vascular endothelial growth factor (VEGF) in macrophages at the BBB. In turn, inducible reduction of GLUT1 expression specifically in BECs reduces brain glucose uptake and increases VEGF serum concentrations in lean mice. Conversely, myeloid-cell-specific deletion of VEGF in VEGFΔmyel mice impairs BBB-GLUT1 expression, brain glucose uptake, and memory formation in obese, but not in lean mice. Moreover, obese VEGFΔmyel mice exhibit exaggerated progression of cognitive decline and neuroinflammation on an Alzheimer’s disease background. These experiments reveal that transient, HFD-elicited reduction of brain glucose uptake initiates a compensatory increase of VEGF production and assigns obesity-associated macrophage activation a homeostatic role to restore cerebral glucose metabolism, preserve cognitive function, and limit neurodegeneration in obesity.

INTRODUCTION

Over the last years, it has become evident that homeostatic signals, as exemplified by leptin (Zhang et al., 1994), communicate energy storage of the organism to the brain to adapt behavioral and autonomic responses in control of energy homeostasis (Gautron et al., 2015; Kleinridders et al., 2009a). Importantly, high-fat diet (HFD) feeding can cause a state of neuronal leptin and insulin resistance to promote positive energy balance (Vogt and Brüning, 2013; Williams and Elmquist, 2012). Here, the manifestation of neuronal insulin and leptin resistance has been linked to the activation of inflammatory signaling cascades, similar to what is observed in peripheral metabolic tissues, such as liver, skeletal muscle, and adipose tissue of obese animal models and humans (Gregor and Hotamisligil, 2011; Kleinridders et al., 2009b; Tsaoousidou et al., 2014). However, the exact mechanism(s) of how inflammatory signaling cascades are activated in obesity remain only partly defined. In this respect, it is remarkable how rapidly shifting animals to high-fat-containing, energy-dense food reprograms metabolism and concomitantly regulates inflammation. Within only 3 days of HFD feeding, expression of proinflammatory cytokines increases in the hypothalamus of rodents as the key regulatory center in energy and glucose homeostasis (Thaler et al., 2012). These acute changes are later accompanied by a whole array of cellular responses, including gliosis,
alterations in brain vasculature, and blood-brain barrier (BBB) integrity (Kälin et al., 2015; Thaler et al., 2012; Yi et al., 2012a, 2012b). Despite all this knowledge on the acute effects of altered nutrition and acutely shifting systemic metabolism to fat utilization, the consequences of this intervention for the brain as an organ critically depending on sustained energy supply, covered primarily by glucose metabolism, remain largely undefined.

Glucose uptake—also in the CNS—occurs primarily by facilitated diffusion through a family of specific glucose transporters. Glucose transporter 1 (GLUT1), encoded by SLC2A1, is the predominant glucose transporter expressed on vascular endothelial cells of the BBB (Takata et al., 1990). Alterations of GLUT1 expression have severe consequences, underlining the critical importance of this transporter to ensure glucose uptake in the brain in addition to further roles in other tissues (Freemerman et al., 2014; Heilig et al., 2003; Macintyre et al., 2014; Wang et al., 2006). Thus, homozygous inactivation of the Slc2a1 gene in mice leads to embryonic lethality (Wang et al., 2006). Already, heterozygous Slc2a1 knockout mice exhibit impaired motor function as well as spontaneous seizures, therefore mimicking the major features of the human GLUT1-deficiency syndrome (GLUT1-DS), where haploinsufficiency of the Slc2a1 gene is the cause of a rare form of encephalopathy (Wang et al., 2006). Here, the functional deficiency of the GLUT1 protein limits brain glucose availability and is characterized by infantile seizures, developmental delay, and acquired microcephaly (De Vivo et al., 1991; Seidner et al., 1998). Recently, it was shown that GLUT1 is of paramount importance for maintenance of capillary networks, blood flow, and BBB integrity, and reductions in GLUT1 levels contribute to neuronal dysfunction and neurodegeneration in mice (Winkler et al., 2015). In individuals with Alzheimer’s disease (AD), GLUT1 expression at the BBB has been reported to decrease (Horwood and Davies, 1994; Kalaria and Harik, 1989; Mooradian et al., 1997; Vannucci et al., 1994). However, the GLUT1-dependent regulation of brain glucose uptake in obesity has so far not been directly addressed.

In order to define the potential acute HFD feeding-elicted changes in cerebral glucose metabolism, we examined the regulation of brain glucose transporters in response to HFD feeding. We find that GLUT1 expression decreases in response to HFD feeding, leading to transiently decreased brain glucose uptake. Upon prolonged HFD feeding, GLUT1 expression is restored in brain endothelial cells (BECs), which is paralleled by increased recruitment and VEGF expression of perivascular macrophages and increased circulating VEGF concentrations. In turn, short-term treatment of mice with recombinant vascular endothelial growth factor (VEGF) can prevent the acute brain glucose uptake-inhibitory effect of HFD feeding. Genetically mimicking partial, acute reduction of GLUT1-BBB expression similarly reduces brain glucose uptake and evokes a compensatory increase in circulating VEGF concentrations. Moreover, myeloid-cell-specific ablation of VEGF in mice reduces BBB-GLUT1 expression, brain glucose uptake, memory formation, and aggravates AD progression in obese but not in lean mice. Collectively, our experiments reveal a critical role for VEGF and HFD-elicted activation of inflammation to ensure cerebral glucose metabolism and to limit progression of neurodegeneration in obesity.

RESULTS

Acute HFD Feeding Impairs Brain Glucose Uptake

Acute HFD feeding rapidly reprograms systemic metabolism and fuel usage (Lee et al., 2011; Thaler et al., 2012). This notion was further substantiated when we assessed systemic substrate usage via indirect calorimetry in mice upon acutely switching feeding from normal chow diet (NCD) to high-fat diet (HFD). Metabolism under these conditions acutely shifts from circadian, alternating carbohydrate and fat usage to a permanent predominance of fat utilization, a phenomenon that is accompanied by rapid weight gain and increased glycemia (Figures 1A, S1A, and S1B). We next aimed to investigate how cerebral glucose metabolism acutely adapts to HFD feeding and its accompanying alterations in systemic substrate usage. To this end, we first compared the mRNA expression of critical glucose transporters in the CNS of mice, which had either remained on NCD feeding or had been switched to HFD feeding for 3 days. This analysis revealed a dramatic 50% downregulation of Slc2a1 expression, while expression of Slc2a3 and Slc2a5 remained unaltered (Figure 1B). When we further assessed the dynamics of brain Slc2a1 expression upon acute HFD feeding, we found that brain Slc2a1 mRNA expression was transiently reduced as early as 3 days of HFD feeding and remained suppressed until 1 week of HFD feeding, while it slowly recovered 2 weeks after HFD feeding initiation and was restored to comparable extend to that observed in constantly NCD fed animals after 4 weeks of HFD feeding (Figure 1C).

Next, we directly assessed GLUT1 protein expression in BECs via immunofluorescent staining for endothelial-cell-specific lectin and GLUT1. GLUT1 immunoreactivity was significantly reduced in BECs between 3 and 7 days after HFD feeding initiation and was restored to comparable extent to that observed in constantly NCD fed animals after 4 weeks of HFD feeding (Figure 1D). Taken together, these experiments clearly indicate that acute HFD feeding transiently reduces the expression of the critical glucose transporter for brain glucose uptake, i.e., GLUT1 at the BBB.

In order to investigate potential compensatory mechanisms, which could account for restoration of GLUT1 expression upon prolonged HFD feeding, we monitored circulating VEGF concentrations, as VEGF is able to upregulate GLUT1 expression at the blood-brain barrier (Lee et al., 2007; Mani et al., 2003; Pekala et al., 1990; Sone et al., 2000; Yeh et al., 2008). Assessment of circulating VEGF concentrations revealed significantly increased serum VEGF concentrations 4 weeks after initiation of HFD feeding, concomitant with full restoration of BBB-GLUT1 expression at this time (Figure 1E). To investigate the origin of increased VEGF production upon HFD feeding, we monitored Vegfa mRNA expression in spleen, liver, and adipose tissue at different times of HFD feeding. This analysis revealed that Vegfa mRNA expression only transiently increased in the spleen 7 days after initiation of HFD feeding (Figures S1D–S1F). However, this transient upregulation clearly cannot account for the prolonged increase in circulating VEGF concentrations and potentially the prolonged restoration of BBB-GLUT1 expression upon chronic HFD feeding.
Since CD206-positive macrophages are a rich source of VEGF production (He et al., 2012), we next assessed the abundance of these cells at the BBB and their VEGF immunoreactivity at different times following initiation of HFD feeding. Both the number and VEGF immunoreactivity of perivascular, CD206-positive macrophages increased as early as 5 days after HFD feeding, increased constantly until 14 days after HFD feeding initiation, and was persistently elevated up to 28 days into HFD feeding (Figures 1F, 1G, and S1G).

Next, we aimed to directly investigate whether acute HFD feeding indeed reduced brain glucose uptake as suggested by reduced BBB-GLUT1 mRNA and protein expression. To this end, we employed $^{18}$F-FDG positron emission tomography (PET) scans to quantitatively assess brain glucose uptake. Therefore, wild-type animals were subjected to $^{18}$F-FDG PET scans and thereafter either remained on NCD or switched to HFD for 3 days. After 3 days, the $^{18}$F-FDG PET scan was repeated and brain glucose uptake was compared to the baseline scan of the same animals. While repeated $^{18}$F-FDG PET scans in animals, which remained on NCD, expectedly revealed no decrease in brain glucose uptake (Figures S2A–S2D), animals that were placed on HFD for 3 days exhibited significantly...
reduced glucose uptake in motor and sensory cortex, hypothalamus, and nucleus accumbens compared to their baseline scan (Figures 2A–2E), revealing that diet-induced reduction of GLUT1 expression also functionally translated in reduced brain glucose uptake.

To investigate whether the restored GLUT1 expression observed upon prolonged HFD feeding also translated into a functional restoration of brain glucose uptake in these mice, we investigated another cohort of mice, in which serial 18F-FDG PET scans were performed before onset of HFD feeding, as well as 3 and 21 days after HFD feeding. This analysis confirmed the robust suppression of brain glucose uptake in mice fed HFD for 3 days, but failed to detect a significant reduction of brain glucose uptake in mice fed a HFD for 21 days compared to the baseline scan under NCD feeding (Figures S2E–S2H).

To test whether VEGF can indeed counteract the HFD feeding-induced suppression of brain glucose uptake, we performed a rescue experiment, where mice were injected twice daily either with saline or recombinant VEGF during an acute 3-day exposure to HFD feeding, followed by 18F-FDG PET scans. This treatment increased serum VEGF concentrations comparable to those observed in wild-type mice fed HFD for 4 weeks (Figures 1E and S2I). Glucose uptake in the VEGF-treated mice returned back to baseline levels in the cortex and even increased in the hypothalamus and the nucleus accumbens (Figures 2F–2J) compared to saline-injected control mice.

Saturated Fatty Acids Suppress BBB-GLUT1 Activity

In order to identify potential mediators of HFD-induced down-regulation of BBB-GLUT1 expression, we first investigated whether serum of animals, which were exposed to HFD for 3 days, contained factors capable of decreasing GLUT1 expression in BECs. To this end, we incubated immortalized BECs for 24 hr with serum of mice, which were kept on NCD or fed an HFD for 3 days. qPCR analysis revealed a robust 90% reduction of Slc2a1 mRNA expression upon incubation with HFD serum (Figure 3A). Similarly, GLUT1 protein expression was robustly repressed by incubating BECs with serum of short-term HFD fed mice (Figure 3B).

Figure 2. High-Fat Diet Acutely Downregulates Brain Glucose Uptake In Vivo
(A) Images showing differential regional glucose uptake in animals before and three days after exposure to HFD. Color code represents the p value for the indicated voxels in a paired Student’s t test before and after diet exposure for nine animals. Reductions in glucose uptake are shown in blue color.
(B–E) Quantification of brain glucose uptake before and 3 days after HFD-exposure in nine animals in the hypothalamus (B), motor cortex (C), somatosensory cortex (D), and nucleus accumbens (E). Data were analyzed using a paired Student’s t test.
(F) Differential regional glucose uptake in animals treated with recombinant VEGF-164 or with saline (n = 8/9) while exposed to HFD for 3 days. Increase in glucose uptake is shown in red color, decrease in blue color.
(G–J) Quantification of changes in glucose uptake in VEGF-164 and saline-treated animals (n = 8/9) in the hypothalamus (G), motor cortex (H), somatosensory cortex (I), and nucleus accumbens (J). Results presented as mean ± SEM or as box plots. Upper and lower whiskers indicate the minimum and maximum values of the data, centerlines indicate the median and the mean values are represented by plus signs. *p < 0.05, **p < 0.01. See also Figure S2.
Next, we hypothesized that altered lipid composition of serum of HFD-fed mice might contribute to its ability to decrease glucose uptake in BECs. We analyzed the serum content of non-esterified fatty acids (NEFAs) of mice kept on either NCD or fed an HFD for 3 days. This analysis revealed an increase of NEFA serum concentrations in HFD-fed mice (Figure 3C). Therefore, we assessed whether saturated fatty acids might functionally impair glucose uptake and subsequent glycolysis in BECs. Indeed, incubating these cells with palmitic acid resulted in decrease of glucose uptake (Figure 3D) and glycolytic flux (Figures 3E–3G). Furthermore, we found that recombinant VEGF could prevent palmitic acid-induced suppression of glucose uptake and glycolysis in these cells (Figures 3D–3G).

**Inducible GLUT1 Deletion in BECs Reduces Brain Glucose Uptake and Increases Circulating VEGF Concentrations**

In order to investigate whether reducing GLUT1 expression to similar extent as observed upon acute HFD feeding reduces brain glucose uptake and potentially elicits a compensatory increase in circulating VEGF concentrations, we aimed to genetically reduce expression of GLUT1 specifically in BECs of adult mice. To this end, we crossed mice that carry a loxP-flanked \( \text{Slc2a1} \) allele (Wei et al., 2015) with those expressing a CreERT2-fusion protein under control of the thyroxine transporter \( \text{Slco1c1} \)-promoter specifically in BECs (Ridder et al., 2011), thus allowing for BEC-specific, tamoxifen-inducible deletion of GLUT1. To investigate the consequences of acute, dose-dependent reduction of GLUT1 expression in BECs, we used both mice heterozygous for the floxed \( \text{Slc2a1} \) allele (\( \text{Slc2a1}^{\text{lox/}+} \) \( \text{Slco1c1}^{\text{-CreERT2}+/\text{C}} \), i.e., \( \text{GLUT-1 iD}^{\text{+/BBB}} \) mice) as well as those homozygous for the \( \text{Slc2a1} \) floxed allele (\( \text{Slc2a1}^{\text{lox/lox}} \) \( \text{Slco1c1}^{\text{-CreERT2}+/\text{C}} \), i.e., \( \text{GLUT-1 iD}^{\text{BBB}} \) mice). After tamoxifen treatment for 3 days, brain cortices of control, \( \text{GLUT-1 iD}^{\text{+/BBB}} \) mice, and \( \text{GLUT-1 iD}^{\text{BBB}} \) mice were analyzed for \( \text{Slc2a1} \) expression via qPCR and by co-immunohistochemistry for GLUT1 and lectin (Figures 4A, 4B, and S3B). This analysis revealed successful reduction of \( \text{BEC GLUT1} \) expression by 40% in \( \text{GLUT-1 iD}^{\text{+/BBB}} \) mice and 67% in \( \text{GLUT-1 iD}^{\text{BBB}} \) mice (Figure 4B).

Acutely, partially reducing \( \text{BEC GLUT1} \) expression resulted in a profound mortality of \( \text{GLUT-1 iD}^{\text{BBB}} \) mice, which all died of seizures within 4 days of tamoxifen-treatment initiation (Figure 4C). On the other hand, reducing \( \text{BEC GLUT1} \) expression acutely by 40% in \( \text{GLUT-1 iD}^{\text{+/BBB}} \) mice resulted in significant mortality of 50% over a 28-day period following initiation of tamoxifen treatment (Figure 4C). These experiments revealed the profound consequences of even partial, acute downregulation of \( \text{BEC GLUT1} \) expression in adult mice.

When we next compared brain glucose uptake via \( ^{18}\text{F-FDG PET} \) scans before and after tamoxifen treatment, both

![Figure 3. Serum of HFD-Fed Mice and Palmitic Acid Acutely Suppresses Glucose Uptake in Cultured BECs](image-url)
GLUT-1<sup>i</sup>/+BBB mice and GLUT-1<sup>i</sup>BBB mice exhibited a dose-dependent reduction of brain glucose uptake (Figures 4D, 4E, S3A, and S3C–S3F). Strikingly, the reduction of brain glucose uptake in GLUT-1<sup>i</sup>/+BBB mice was quantitatively comparable to that observed in key glucose sensing regions of mice fed an HFD for 3 days (Figures 2A–2E).

Moreover, longitudinal assessment of serum VEGF concentrations in these animals revealed that in GLUT-1<sup>i</sup>BBB mice, after 3 days of tamoxifen treatment, serum VEGF concentrations had increased more than 2-fold compared to tamoxifen-treated control mice (Figure 4F). In GLUT-1<sup>i</sup>/+BBB mice, VEGF concentrations significantly increased between 5 and 14 days after initiation of tamoxifen treatment (Figure 4F).

### Myeloid-Cell-Derived VEGF Is Required to Maintain BBB-GLUT1 Expression in Obesity

To test whether VEGF upregulation in macrophages is indeed causally required for restoration of BBB-GLUT1 expression and brain glucose metabolism upon prolonged HFD feeding, we decided to investigate the consequence of ablating VEGF expression from myeloid lineage cells on BBB-GLUT1 expression and brain glucose metabolism in obesity. Here, we crossed mice carrying a loxP-flanked <i>Vegfa</i> allele (Gerber et al., 1999) with those expressing the Cre-recombinase in myeloid lineage cells under control of the lysozyme (Lys)M-promoter (Clausen et al., 1999). Resulting VEGF<sup>lox/lox</sup> LysMCre<sup>+/−</sup>, i.e., VEGF<sup>Δmyel</sup> mice were then analyzed exposing the animals to either NCD or HFD after...
weaning. Analysis of serum VEGF levels confirmed the increase in circulating VEGF concentrations in control HFD-fed mice compared to NCD-fed controls and revealed a profound reduction in circulating VEGF concentrations in VEGFΔmyel mice, both on NCD and HFD (Figure 5A). Comparing body weights revealed no significant differences between genotypes, while animals of both genotypes also gained indistinguishably body weight or fat mass upon exposure to HFD, consistent with unaltered steady-state food intake of these animals (Figures S4A–S4C). Similarly, systemic glucose homeostasis remained unaltered in NCD-fed control and VEGFΔmyel mice as assessed by glucose tolerance testing (Figure 5B). In contrast, HFD-fed VEGFΔmyel mice exhibited an impaired glucose tolerance compared to control mice, when the animals were exposed to HFD feeding (Figure 5B).

There was no significant difference in Slc2a1 mRNA expression between control and VEGFΔmyel mice fed an NCD (Figure 5C), indicating that myeloid-derived VEGF is not required to control BBB-GLUT1 expression in lean mice. However, VEGFΔmyel mice exhibited significantly reduced Slc2a1 mRNA expression compared to controls under HFD feeding (Figure 5C). The notion that myeloid-cell-derived VEGF is required for maintenance of BEC-GLUT1 expression under HFD conditions was
further substantiated through co-immunohistochemical staining of GLUT1 in lectin-positive BECs. Here, GLUT1 immunoreactivity remained unaltered in control and VEGF<sup>amyel</sup> mice under NCD, while VEGF<sup>amyel</sup> mice exhibited significantly reduced GLUT1 immunoreactivity compared to controls under HFD (Figures 5D, 5E, S4D, and S4E). Consistent with the restoration of BEC GLUT1 expression 4 weeks after HFD feeding, in control animals prolonged HFD feeding did not result in reduced GLUT1 immunoreactivity in BECs, indicating that indeed upregulated VEGF can restore normal BBB-GLUT1 expression upon chronic HFD feeding even in long-term (Figures 5D and 5E).

To directly investigate the consequences of reduced BBB-GLUT1 expression in HFD-fed VEGF<sup>amyel</sup> mice, we quantified brain glucose uptake in these animals compared to controls exposed to HFD feeding during euglycemic hyperinsulinemic clamps. This analysis revealed a significant reduction of brain glucose uptake in these animals (Figures S4F=S4H). While insulin-stimulated suppression of hepatic glucose production and insulin-stimulated glucose uptake into WAT remained unaltered in these mice, insulin-stimulated glucose uptake into skeletal muscle tended to be increased in VEGF<sup>amyel</sup> mice, although not reaching statistical significance (Figures S4F–S4H).

Interestingly, we found increased deposits of extravascular immunoglobulin G (IgG) in the cortex of VEGF<sup>amyel</sup> mice on HFD, but not upon NCD feeding, indicating increased vascular leakage as evidence for altered BBB-permeability in these animals (Figures 5F and 5G).

Given that brain glucose availability is critical for neuronal function, including cognitive performance, we next compared the ability of the different groups of mice at the age of 16 months to properly establish spatial memory in a Morris water maze task. While in lean and obese control mice, as well as in lean VEGF<sup>amyel</sup> mice, the time required to locate the hidden platform similarly decreased during the training sessions, obese VEGF<sup>amyel</sup> mice tended to require more time to locate the platform (Figure 5H). Upon removal of the platform, VEGF<sup>amyel</sup> mice exposed to HFD performed significantly worse to retain spatial memory compared to the NCD-fed groups of mice (Figure 5I).

**Myeloid-Cell-Derived VEGF Limits Neurodegeneration in Obesity**

In light of the discovery that VEGF is required to maintain brain glucose uptake and cognitive function in obesity, and brain glucose uptake is a critical determinant of the progression of neurodegenerative disorders such as Alzheimer’s disease (AD) (Gong et al., 2006; Winkler et al., 2015), we decided to address whether myeloid-cell-derived VEGF is also required to limit neurodegeneration in obesity in a murine AD model. To this end, we crossed VEGF<sup>amyel</sup> mice with APP.PS1-transgenic mice, expressing the Swedish mutation of amyloid precursor protein (APP) and also expressing a variant of presenilin (PS)-1 (Jankowsky et al., 2004). Further intercrossing of these animals resulted in four different experimental groups of mice, (1) control animals, (2) APP.PS1-transgenic mice, (3) VEGF<sup>amyel</sup> mice, and (4) VEGF<sup>amyel</sup> mice, which express the APP.PS1-transgenes.

First, we compared GLUT1 expression in BECs in the different lines of animals both in cortex and hippocampus. Consistent with what we observed in VEGF<sup>amyel</sup> mice compared to controls on NCD, lean VEGF<sup>amyel</sup> mice generated from these intercrosses exhibited unaltered GLUT1 expression in BECs (Figures S5A–S5D). APP.PS1-transgenic mice exhibited unaltered BBB-GLUT1 expression under NCD and this remained unchanged in the additional absence of myeloid-cell-derived VEGF in lean VEGF<sup>amyel</sup>/APP.PS1 mice (Figures S5A–S5D).

Upon HFD feeding, however, mRNA and protein expression of BBB-GLUT1 expression decreased to similar extent in both VEGF<sup>amyel</sup> and VEGF<sup>amyel</sup>/APP.PS1 mice in cortex (Figures 6A, 6B, and 6D) as well as BBB-GLUT1 protein expression decreased in hippocampus (Figures 6C and 6E).

Since cognitive deficits have been reported to manifest at the age of 9 months in APP.PS1-transgenic mice (Jankowsky et al., 2004), we aimed to test, whether impairment of brain glucose uptake in HFD-fed VEGF<sup>amyel</sup>/APP.PS1 mice could aggravate this phenotype and therefore assessed spatial memory learning in 6-month-old mice. Indeed, already at this young age only VEGF<sup>amyel</sup>/APP.PS1 mice, when exposed to HFD, performed significantly worse compared to all other tested genotypes (Figures 6F and 6G). These data indicate that HFD feeding in the presence of reduced circulating VEGF concentrations aggravates cognitive defects in APP.PS1-transgenic mice.

Next, we aimed to investigate the molecular basis for aggravated memory impairment of VEGF<sup>amyel</sup>/APP.PS1 mice and therefore quantified amyloid plaque burden in the different groups of mice. While plaque burden was significantly increased in the presence of the APP.PS1-transgene, A<sub>b</sub>-plaque formation was not further aggravated in the absence of myeloid-cell-derived VEGF both in NCD- and HFD-fed animals (Figures 7A, 7B, S6A, and S6B). Similarly, brain levels of A<sub>β</sub>-<sub>42</sub> as assessed by ELISA detection remained unaltered in the absence of myeloid-derived VEGF in APP.PS1-transgenic mice (Figure S6C). Thus, impairing brain glucose metabolism on an AD background does not aggravate plaque formation.

To study the underlying mechanism by which the absence of myeloid-derived VEGF impaired cognitive function in APP.PS1-transgenic mice, vascular leakage was assessed by quantification of extravascular accumulation of IgG. This analysis confirmed a significant increase in IgG deposits in the absence of myeloid-derived VEGF as an additional evidence of altered BBB functionality in these obese mice (Figures 7C and 7D).

Another hallmark in AD progression is the activation of neuro-inflammation. Thus, we determined the distribution of GFAP immunoreactivity as readout for astrocyte activation in the brains of the different animals. This analysis revealed that in APP.PS1-transgenic animals, the number of GFAP-immunoreactive cells clearly increased both in cortex and hippocampus (Figures 7E, 7F, S7A, and S7B). However, under HFD feeding conditions, the additional absence of myeloid-derived VEGF and thus subsequently reduced brain glucose uptake caused a further significant increase in GFAP immunoreactivity in HFD-fed VEGF<sup>amyel</sup>/APP.PS1 mice (Figures 7E, 7F, S7A, and S7B). In addition, immunoreactivity of phosphorylated c-Jun (p-c-Jun) as readout for inflammatory JNK-activation was further substantially increased under these conditions in HFD-fed VEGF<sup>amyel</sup>/APP.PS1 mice (Figures 7G, 7H, S7C, and S7D).
Taken together, reducing brain glucose uptake through HFD feeding and simultaneously preventing the compensatory increase in circulating VEGF cooperates with APP.PS1-driven neurodegeneration through aggravation of neuroinflammation without increasing Aβ1–42 processing or plaque burden. Thus, circulating VEGF is also critically required to limit AD-associated cognitive impairment and progression of neuroinflammation in obesity.

**DISCUSSION**

We demonstrate that acute HFD feeding in mice transiently reduces GLUT1 expression in BECs of the BBB (BECs) and functionally reduces brain glucose uptake. This finding is further substantiated by the notion that incubation of BECs with serum derived from mice exposed to high-fat diet...
A

Number of amyloid plaques

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

n.d. n.d.

B

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

A\textsubscript{β}(6E10) MERGE/DAPI

C

Extracellular IgG (fold change)

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

D

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

Lectin/IgG

E

Immunostaining GFAP (AU)

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

Cortex

**

F

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

GFAP MERGE/DAPI

G

Immunostaining p-c-Jun (AU)

Control Vegf\textsuperscript{myel} APP.S1 Vegf\textsuperscript{myel}/APP.S1

Cortex

*
feeding for 3 days significantly reduces GLUT1 mRNA and protein expression. This clearly indicates the presence of soluble factor(s) in serum of these animals, which are responsible for reducing GLUT1 expression in BECs. We also demonstrate that palmitic acid as a saturated fatty acid, which is increased in circulation of obese mice (Benoit et al., 2009; Boden, 1997), acutely inhibits glucose uptake and glycolytic metabolism in cultured BECs. Thus, saturated fatty acids may provide an interesting candidate to mediate BBB-GLUT1 downregulation in obesity. However, the exact nature of these signal(s) and the molecular mechanisms activated to decrease GLUT1 expression in BECs remains to be identified in further studies.

Another important question is how transiently lowered brain glucose uptake leads to increased circulating VEGF concentrations and ultimately to restored BBB-GLUT1 expression. Our experiments reveal that the primary source of compensatory VEGF production in obesity is myeloid lineage cells, likely CD206-positive perivascular macrophages. Although a minor component of the CNS, perivascular macrophages are important immunoregulatory cells (Galea et al., 2005; Williams et al., 2001). These cells appear to account for the majority of increased VEGF during the first 4 weeks of HFD feeding, when no persistent increases of VEGF expression in spleen, liver, and adipose tissue are detectable. It appears likely that during the further course of obesity development, macrophages recruited to adipose tissue may also contribute to the compensatory increase in circulating VEGF concentrations. This notion is consistent with the previous reports of elevated VEGF release from visceral adipose tissue of obese subjects (Schlich et al., 2013).

Future experiments will have to delineate how reduced brain glucose uptake couples to activation of perivascular macrophages to increase VEGF production and ultimately re-instantiate GLUT1 expression at the neurovascular unit. One possibility is that glucose-sensitive neurons, which respond to changes in extracellular glucose concentration (Steinbusch et al., 2015), can regulate parasympathetic outflow, which in turn activates inflammation. The reduction of brain glucose uptake reported here on acute HFD feeding is particularly predominant in areas that are enriched in glucose-sensing neurons such as the hypothalamus (Karschin et al., 1997; Levin et al., 1999; Peters et al., 2004). Reduction of parasympathetic tone is well documented in obesity and has been demonstrated to contribute to the activation of inflammation of obesity (Andersson and Tracey, 2012; Rosas-Ballina and Tracey, 2009). In fact, specific activation of parasympathetic α7-nicotinic receptors can limit obesity-induced inflammation and improve obesity-associated systemic insulin resistance (Bencherif et al., 2011; Wang et al., 2011). Clearly, further studies have to define the neurocircuitry, which couples reduced neuronal glucose availability to the activation of VEGF production in macrophages, both in the BBB and in other tissues.

Given the critical role of tight control of brain glucose availability for organismal survival, activation of VEGF expression and inflammation upon transient reduction of brain glucose metabolism provides a prime mechanism to reinstate glucose availability to the CNS. First, increased VEGF concentrations can restore glucose uptake in BECs, as shown here in vitro and in vivo. Second, activation of systemic inflammation causes insulin resistance in skeletal muscle and adipose tissue (Sabio et al., 2008), thereby reducing insulin-stimulated glucose uptake in these tissues and impairing insulin-stimulated suppression of hepatic glucose production (Arkan et al., 2005; Sabio et al., 2008; Wunderlich et al., 2008). Thus, blood glucose concentrations increase and thereby provide increased substrate availability for the CNS. This concept would define obesity-associated inflammation as a homeostatic regulatory principle to restore transiently decreased brain glucose uptake in obesity through multiple mechanisms.

The notion that activation of inflammatory signaling represents a key step in the development of obesity-associated insulin resistance has fueled a whole research area to identify anti-inflammatory strategies as novel drug targets for this disease (Gregor and Hotamisligil, 2011; Hotamisligil, 2006). However, currently the efficiency of anti-inflammatory strategies is solely assessed based on their ability to improve peripheral insulin sensitivity and glucose metabolism. Thus, when inflammatory signaling pathways are targeted in metabolic diseases, attention will have to be paid to the potential side effects of the intervention on compensatory VEGF production and its potential detrimental effects on brain glucose metabolism, cognition, and neurodegeneration.

Finally, our results may have clear implications for further strategies targeting neurodegenerative disorders such as AD. Recent studies have revealed a critical role for brain glucose metabolism in AD progression. On the one hand, glucose availability has been implicated in the activity-dependent co-secretion of Aβ-peptides and thus contributes to activity-dependent progression of neurodegeneration (Macaulay et al., 2015). On the other hand, it was demonstrated that partially reducing BBB-GLUT1 expression leads to massive progression of AD pathology in mouse models (Winkler et al., 2015). Interestingly, the latter phenomenon occurred in the absence of alterations in Aβ-processing and accumulation, similar to what is observed in our VEGFΔmyel/APP.PS1 mice under high-fat diet conditions.
Collectively, our study assigns VEGF a critical compensatory role to reinstate brain glucose metabolism in obesity, a notion of far-reaching therapeutic implications not only for obesity, but also cancer treatment and that of neurodegenerative disorders in obese subjects, setting the ground for more personalized therapeutic decisions in obese patients in the future.

**EXPERIMENTAL PROCEDURES**

**Animal Husbandry**
All animal procedures were conducted in compliance with protocols approved by local government authorities (Bezirksregierung Köln) and were in accordance with NIH guidelines. Mice were housed in groups of three to five at 22°C–24°C using a 12 hr light/12 hr dark cycle. Animals had ad libitum access to water at all times, and food was only withdrawn if required for an experiment. All mouse models are described in the Supplemental Experimental Procedures.

**Indirect Calorimetry**
Indirect calorimetry measurements were performed as described in the Supplemental Experimental Procedures.

**Immunohistochemistry**
Immunohistochemistry was performed as described in the Supplemental Experimental Procedures.

**PET Imaging**
PET imaging was performed using an Inveon preclinical PET/CT system (Siemens) as described in the Supplemental Experimental Procedures.

**Culture of Cerebral Endothelial Cells**
The immortalized mouse brain capillary EC line cerebral endothelial cells (cEND) were used as described (Förster et al., 2005) and outlined in the Supplemental Experimental Procedures.

**Glucose Uptake Assay**
Cellular glucose uptake was measured in cEND cells using a fluorescent 2-NBDG assay. For details, refer to the Supplemental Experimental Procedures.

**Measurement of Glycolytic Flux**
Extracellular acidification rate (ECAR) was measured using the XF96 Flux Analyzer (Seahorse Bioscience). For details, see Supplemental Experimental Procedures.

**Glucose Tolerance Test**
Glucose tolerance tests were performed as previously described in (Tovar et al., 2013) and as outlined in the Supplemental Experimental Procedures.

**Hyperinsulinemic-Euglycemic Clamp Studies in Awake Mice**
Clamp experiments were performed as outlined in the Supplemental Experimental Procedures.

**Morris Water Maze**
The Morris water maze was used to test spatial learning and to evaluate the working and reference memory functions. Lean or obese VEGF<sup>amy555</sup> mice and control mice were tested at 16 months of age. Obese HFD-fed APP,PS1-transgenic mice, VEGF<sup>amy555</sup> mice, VEGF<sup>amy555/APP,PS1</sup> mice, and corresponding controls were tested at 6 months of age. For details see the Supplemental Experimental Procedures.

**Statistical Analyses**
All data, unless otherwise indicated, are shown as mean values ± SEM. In boxplots, the upper and lower whiskers indicate the minimum and maximum values of the data, center lines indicate the median, and the mean values are represented by plus signs. Datasets with only two independent groups were analyzed for statistical significance using unpaired two-tailed Student’s t test. Datasets with more than two groups were analyzed using either one-way ANOVA followed by Tukey’s post hoc test or two-way ANOVA followed by Tukey’s post hoc test. For statistical analyses of GTTs, we performed two-way ANOVAs followed by Bonferroni’s post hoc test. All figures and statistical analyses were generated using GraphPad Prism 6. p < 0.05 was considered to indicate statistical significance.

**Other Methods**
See the Supplemental Experimental Procedures.

**SUPPLEMENTAL INFORMATION**
Supplemental Information includes Supplemental Experimental Procedures and seven figures and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2016.03.033.

**AUTHOR CONTRIBUTIONS**

**ACKNOWLEDGMENTS**
This work was supported by a grant from the DFG (BR 1492/7-1) to J.C.B., and received funding by the DFG within the framework of the TRR134 and within the CMMC and the Excellence Initiative by German Federal and State Governments (CECAD). This work was funded (in part) by the Helmholtz Alliance ICEMED (Imaging and Curing Environmental Metabolic Diseases) through the Initiative and Networking Fund of the Helmholtz Association. Moreover, the research leading to these results has received funding from the European Union Seventh Framework Program (FP7/2007–2013) under grant agreement 296408. S.M.S. was funded by the Humboldt-Bayer program of the Alexander Von Humboldt foundation and received a grant from the Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (CECAD). A.K. was supported by a DFG fellowship KL2399-3/1. S.T. was funded by a scholarship-program (Gerok-Rotationsstelle, No. 3/2014) of the Medical Faculty of the University of Cologne. G.K. was funded by the National Institute on Aging (NIH grant 1R01DK104727-01A1. [18F]FDG was provided by B. Neumaier and the radiochemistry department of the Max Planck Institute for Metabolism Research.

Received: August 27, 2015
Revised: January 25, 2016
Accepted: March 16, 2016
Published: April 28, 2016

**REFERENCES**


Williams, K., Alvarez, X., and Lackner, A.A. (2001). Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 36, 156–164.


